Suppression of Erosive Arthritis by NF-κB Inhibitors

Author(s): Tetsuo Kubota, Kazuo Umezawa

Journal Name: Current Rheumatology Reviews

Volume 7 , Issue 4 , 2011

Become EABM
Become Reviewer


Excess activation of NF-kappa B is often involved in inflammation and cancer progression. We have developed a specific NF-kappa B inhibitor dehydroxyepoxyquinomicin (DHMEQ). It binds to the specific cysteine residue of Rel family proteins. DHMEQ inhibited cytokine secretions and osteoclastogenesis in cultured macrophages. It inhibited various animal models of inflammation and cancer. Especially, it inhibited type 2-induced rheumatoid arthritis without any toxicity in mice. It also decreased the number of osteoclasts in the inflammatory tissues. Thus, excess activation of NF-kappa B is essential for rheumatoid arthritis, and DHMEQ is a candidate of new anti-rheumatoid chemotherapeutic agent.

Keywords: NF-kappa B, DHMEQ, macrophage, osteoclast, NFATc1, chemotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [275 - 281]
Pages: 7
DOI: 10.2174/157339711798221077
Price: $65

Article Metrics

PDF: 4